PlumX Metrics
Embed PlumX Metrics

The metabolic time line of pancreatic cancer: Opportunities to improve early detection of adenocarcinoma

The American Journal of Surgery, ISSN: 0002-9610, Vol: 218, Issue: 6, Page: 1206-1212
2019
  • 19
    Citations
  • 0
    Usage
  • 29
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

A reliable biomarker to detect pancreatic ductal adenocarcinoma (PDAC) continues to be elusive. With employing metabolomics we hypothesize that a broader analysis of systemic blood can differentiate different stages of PDAC. Patients undergoing pancreatic resection had plasma samples grouped by diagnosis and assayed with mass spectrometry. 10 per group [neuroendocrine (PNET), intraductal papillary mucinous neoplasm (IPMN), localized PDAC, locally advanced PDAC, and metastatic] were analyzed to assess if metabolites could delineation different stages of adenocarcinoma. Of the 215 metabolites measured, four had a stronger correlation to disease burden than CA19-9. However, none of these metabolites differentiated stepwise progression in malignancy. Principal component analysis identified five metabolic components. Each cancer cohort was characterized by a unique combination of components, two components were predictors of PDCA stages. Enhanced metabolomic analysis identified metabolic pathways that may assist in differentiating PDCA stages that do not occur in a linear stepwise progression.

Bibliographic Details

Moore, Hunter B; Culp-Hill, Rachel; Reisz, Julia A; Lawson, Peter J; Sauaia, Angela; Schulick, Richard D; Del Chiaro, Marco; Nydam, Trevor L; Moore, Ernest E; Hansen, Kirk C; D'Alessandro, Angelo

Elsevier BV

Medicine

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know